Subbiah V, Paz-Ares L, Besse B, et al. - Re-challenge with the first-line treatment (SCLC) with chemotherapy-free interval (CTFI) ≥ 180 days is advised by the National Comprehensive Cancer Network guidelines for relapsed small cell lung cancer, and a phase II analysis demonstrated remarkable antitumor activity with lurbinectedin 3.2 mg/m² 1 -hour intravenous infusion every 3 weeks as second-line therapy among SCLC patients. For this study, they analyzed the impact of lurbinectedin in 20 patients aged ≥18 years with pathologically confirmed SCLC diagnosis and with CTFI  ≥ 180 days who were already treated with only one prior platinum-containing line and had no CNS metastases. The overall response rate evaluated by the Investigators as per RECIST v1.1 was the primary efficacy endpoint. Findings demonstrated the effectiveness of lurbinectedin along with an acceptable safety and tolerability in patients with platinum-sensitive relapsed SCLC, particularly in those with CTFI ≥ 180 days. the ORR was 60.0%, with a median duration of response of 5.5 months and disease control rate of 95.0%; median progression-free survival was 4.6 months. These promising findings indicate that lurbinectedin can serve as another useful treatment choice instead of platinum re-challenge.